Peptides for recovery: BPC-157, TB-500 and the evidence

BPC-157 and TB-500, the peptides most promoted for injury recovery, are not FDA-approved and have almost no human research behind them. BPC-157’s evidence comes mostly from animal studies, and the FDA found no reports of TB-500 being given to people for any condition. Both are banned in sport. An FDA advisory committee voted in July 2026 to recommend letting pharmacies compound them, but that vote is not binding.

Which peptides are promoted for recovery?

The two best known are BPC-157, a synthetic 15-amino-acid peptide originally isolated from gastric juice (McGuire et al., 2025), and TB-500, a seven-amino-acid fragment related to thymosin beta-4 (FDA). Others promoted for healing include KPV for inflammation and GHK-Cu for skin and wounds, while growth hormone peptides such as CJC-1295 / ipamorelin are marketed for “recovery” in a looser sense.

BPC-157: what the research shows

In animals, results look encouraging. In animal studies, BPC-157 was reported to improve healing of muscle, tendon, ligament and bone injuries (Vasireddi et al., 2025). It acts on several pathways involved in blood-vessel growth and repair (McGuire et al., 2025).

In people, there is very little. The one clinical study in the 2025 systematic review was a look back at 12 people with knee pain who had a BPC-157 knee injection, 7 of whom reported relief for more than six months. It had no comparison group, and the review found no clinical safety data (Vasireddi et al., 2025). A second 2025 review counted three small pilot studies in humans and concluded BPC-157 “should be considered investigational” until well-designed trials are done (McGuire et al., 2025).

The FDA’s own review was blunt. Evaluating BPC-157 for ulcerative colitis, the use it was nominated for, the FDA found five small clinical studies, none of which gave BPC-157 by mouth, under the skin, in the nose or on the skin. It concluded that the data “do not support the use of BPC-157 for the treatment of UC”, that the substance is not well characterized, and that no product containing BPC-157 is approved in any country (FDA).

TB-500: what the research shows

TB-500 is often described online as thymosin beta-4, but the FDA says the two “are not the same substance”. Thymosin beta-4 is a natural protein that has been tested in early clinical trials for wound and tissue repair (Goldstein and Kleinman, 2015); TB-500 is a short synthetic fragment, and the protein’s results can’t be assumed to apply to it.

The FDA did not find any report of TB-500 being given to patients for any disease or condition, including wound healing. It found no animal studies testing whether TB-500 promotes wound healing, and a lab study in which TB-500 did not heal scratch wounds in skin cells. The FDA said it is “particularly concerned about the absence of human data” (FDA).

Where do BPC-157 and TB-500 stand legally?

Both are unapproved drugs. The FDA had listed BPC-157, TB-500 and KPV among bulk substances that may present significant safety risks in compounding; the people who nominated them later withdrew the nominations, and the FDA still lists its concerns, including possible immune reactions (FDA).

On July 23 and 24, 2026, the FDA’s Pharmacy Compounding Advisory Committee reviewed seven peptides (FDA). It narrowly voted to recommend adding six of them, including BPC-157, TB-500 and KPV, to the list pharmacies may compound from, although FDA staff scientists had opposed every one (ABC News). Advisory committees make non-binding recommendations, and the FDA would still need to propose and finalize a rule. Even then, a compounded peptide would not be an FDA-approved drug, and being on the list would not mean the FDA had declared it safe or effective (ABC News).

US regulatory status

• BPC-157US status: Not approved

  BPC-157 is not approved by the FDA for any use, and no country has approved a BPC-157 medicine. As of April 2026 the FDA lists it among substances whose nominations were withdrawn from its Category 2 safety-risk list; it is not in Category 1. In July 2026 an FDA advisory committee narrowly voted, against FDA staff advice, to recommend adding it to the 503A bulks list. That vote is not binding, and as of October 16, 2026 the FDA had not published a proposed or final rule. WADA bans it at all times (S0).

  As of October 16, 2026

  Sources4578911

• TB-500US status: Not approved

  TB-500 is not approved by the FDA for any use and is not the same substance as thymosin beta-4. As of April 2026 its nomination had been withdrawn from the FDA’s Category 2 safety-risk list. In July 2026 an FDA advisory committee narrowly voted, against FDA staff advice, to recommend adding it to the 503A bulks list; the vote is not binding, and as of October 16, 2026 no rule had been published. WADA bans thymosin beta-4 and its derivatives, naming TB-500, at all times (S2.3).

  As of October 16, 2026

  Sources24789

• KPVUS status: Not approved

  KPV is not approved by the FDA for any use. As of April 2026 its nomination had been withdrawn from the FDA’s Category 2 safety-risk list, which notes the FDA found no human exposure data by any route. In July 2026 an FDA advisory committee narrowly voted, against FDA staff advice, to recommend adding it to the 503A bulks list; the vote is not binding, and as of October 16, 2026 no rule had been published.

  As of October 16, 2026

  Sources47812

Are recovery peptides banned in sport?

Yes. The World Anti-Doping Agency’s 2026 Prohibited List names BPC-157 among “non-approved substances” and lists thymosin beta-4 derivatives such as TB-500 among prohibited growth factors. Both classes are banned at all times, in and out of competition (WADA). The authors of the 2025 BPC-157 review advise clinicians to make sure athletes understand their organization’s rules (Vasireddi et al., 2025).

Side effects and safety

Nobody knows how safe these peptides are in people, because they have not been studied properly. The FDA’s main concerns are immune reactions to injected peptides and their impurities, and products whose identity and purity are not well established (FDA). A 2026 sports medicine review warned that rigorous human safety data are scarce and that there is potential for serious harm (Mendias and Awan, 2026). Vials sold online add the risks of contamination and wrong contents.

Questions people ask